Emilie C.
- Country
- France
- Department
- Hématologie
Research Overview
- Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Patients with Relapsed/Refractory Multiple Myeloma Following BCMA-Targeting CAR-T or Bispecific Antibody Therapy
- Phase 2, multicenter, open‑label study of extended‑dosing belantamab mafodotin in combination therapy for relapsed/refractory multiple myeloma
Data & Insights
Has run more than one trial at 88 of 185 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in developing innovative treatment approaches for multiple myeloma, with particular focus on therapeutic strategies for both newly diagnosed and relapsed cases.
- Treatment optimization for elderly patients
- Novel drug combinations with daratumumab and lenalidomide
- Minimal Residual Disease assessment
The research extends to evaluating different administration routes and treatment durations to enhance patient outcomes.
Hematologic Malignancies
Expertise in treating various blood cancers and related conditions, with specific attention to innovative therapeutic approaches in:
- Chronic Lymphocytic Leukemia (CLL)
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasms
Research includes investigations into targeted therapies and novel treatment combinations for various hematological conditions.
Clinical Innovations
Leading research in advanced therapeutic approaches and treatment methodologies, including:
- CAR-T cell therapy applications
- Thromboembolism prevention strategies
- Cellular therapy monitoring
Focus on developing personalized treatment approaches and investigating novel drug delivery methods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.